Syros Pharmaceuticals Inc. (NASDAQ:SYRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

SYRS has been the subject of a number of other reports. Piper Jaffray Cos. reissued a “buy” rating and issued a $20.00 price target on shares of Syros Pharmaceuticals in a report on Thursday, September 22nd. Wedbush reissued an “outperform” rating and issued a $18.00 price target on shares of Syros Pharmaceuticals in a report on Monday, November 14th. Finally, HC Wainwright reissued a “hold” rating and issued a $10.00 price target on shares of Syros Pharmaceuticals in a report on Friday, September 9th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Syros Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $17.50.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS) opened at 13.86 on Wednesday. The stock’s 50 day moving average price is $13.52 and its 200-day moving average price is $13.06. The company’s market capitalization is $324.05 million. Syros Pharmaceuticals has a 52-week low of $8.16 and a 52-week high of $21.50.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Monday, November 14th. The company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by $0.11. Analysts predict that Syros Pharmaceuticals will post ($4.03) earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of the stock. Flagship Ventures Fund IV General Partner LLC acquired a new stake in Syros Pharmaceuticals during the second quarter worth approximately $87,241,000. Deerfield Management Co. acquired a new stake in Syros Pharmaceuticals during the second quarter worth approximately $38,028,000. Weiss Multi Strategy Advisers LLC acquired a new stake in Syros Pharmaceuticals during the second quarter worth approximately $832,000. Aisling Capital LLC acquired a new stake in Syros Pharmaceuticals during the second quarter worth approximately $16,490,000. Finally, Baker BROS. Advisors LP acquired a new stake in Syros Pharmaceuticals during the third quarter worth approximately $2,836,000. Institutional investors and hedge funds own 53.43% of the company’s stock.

WARNING: This article was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2016/11/25/syros-pharmaceuticals-inc-syrs-stock-rating-upgraded-by-zacks-investment-research.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.